Compare · SLNO vs STEX
SLNO vs STEX
Side-by-side comparison of Soleno Therapeutics Inc. (SLNO) and Streamex Corp. (STEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SLNO and STEX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 28.4x STEX ($97.3M).
- Over the past year, SLNO is down 33.3% and STEX is down 85.2% - SLNO leads by 51.9 points.
- STEX has been more active in the news (9 items in the past 4 weeks vs 2 for SLNO).
- SLNO has more recent analyst coverage (12 ratings vs 1 for STEX).
- Company
- Soleno Therapeutics Inc.
- Streamex Corp.
- Price
- $53.02+0.08%
- $0.93-8.97%
- Market cap
- $2.76B
- $97.3M
- 1M return
- +0.76%
- -6.16%
- 1Y return
- -33.27%
- -85.19%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 2
- 9
- Recent ratings
- 12
- 1
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest STEX
- Interim Executive Chairman Lekstrom Morgan Lee bought $49,750 worth of shares (50,000 units at $0.99) (SEC Form 4)
- Chief Investment Officer Williams Mitchell Young sold $24,915 worth of shares (23,810 units at $1.05), decreasing direct ownership by 0.78% to 3,013,838 units (SEC Form 4) to satisfy withholding obligation
- Amendment: SEC Form 4 filed by Interim Executive Chairman Lekstrom Morgan Lee
- Amendment: Interim Executive Chairman Lekstrom Morgan Lee bought $147,289 worth of shares (47,000 units at $3.13) (SEC Form 4)
- Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Interim Executive Chairman Lekstrom Morgan Lee bought $49,980 worth of shares (34,000 units at $1.47) (SEC Form 4)
- Streamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset
- Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design
- Director Marciano Anthony Mark bought $20,052 worth of shares (17,745 units at $1.13), increasing direct ownership by 18% to 117,745 units (SEC Form 4)